1. Home
  2. OFS vs NKTX Comparison

OFS vs NKTX Comparison

Compare OFS & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OFS
  • NKTX
  • Stock Information
  • Founded
  • OFS 2001
  • NKTX 2015
  • Country
  • OFS United States
  • NKTX United States
  • Employees
  • OFS N/A
  • NKTX N/A
  • Industry
  • OFS Finance/Investors Services
  • NKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • OFS Finance
  • NKTX Health Care
  • Exchange
  • OFS Nasdaq
  • NKTX Nasdaq
  • Market Cap
  • OFS 117.0M
  • NKTX 123.5M
  • IPO Year
  • OFS 2012
  • NKTX 2020
  • Fundamental
  • Price
  • OFS $8.82
  • NKTX $1.95
  • Analyst Decision
  • OFS
  • NKTX Strong Buy
  • Analyst Count
  • OFS 0
  • NKTX 5
  • Target Price
  • OFS N/A
  • NKTX $13.50
  • AVG Volume (30 Days)
  • OFS 34.2K
  • NKTX 502.7K
  • Earning Date
  • OFS 10-30-2025
  • NKTX 11-06-2025
  • Dividend Yield
  • OFS 15.40%
  • NKTX N/A
  • EPS Growth
  • OFS N/A
  • NKTX N/A
  • EPS
  • OFS 0.76
  • NKTX N/A
  • Revenue
  • OFS $43,337,000.00
  • NKTX N/A
  • Revenue This Year
  • OFS N/A
  • NKTX N/A
  • Revenue Next Year
  • OFS N/A
  • NKTX N/A
  • P/E Ratio
  • OFS $11.55
  • NKTX N/A
  • Revenue Growth
  • OFS N/A
  • NKTX N/A
  • 52 Week Low
  • OFS $7.81
  • NKTX $1.31
  • 52 Week High
  • OFS $9.80
  • NKTX $5.88
  • Technical
  • Relative Strength Index (RSI)
  • OFS 52.60
  • NKTX 40.08
  • Support Level
  • OFS N/A
  • NKTX $2.00
  • Resistance Level
  • OFS $8.79
  • NKTX $2.08
  • Average True Range (ATR)
  • OFS 0.10
  • NKTX 0.10
  • MACD
  • OFS -0.29
  • NKTX -0.03
  • Stochastic Oscillator
  • OFS 99.55
  • NKTX 10.26

About OFS OFS Capital Corporation

OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: